Home Risk Management/Safety FDA head admits controversy over Alzheimer’s drug decision impacted experts’ trust in the agency FDA head admits controversy over Alzheimer’s drug decision impacted experts’ trust in the agencyadmin Apr 04, 2022 0 Comments Robert Califf, the new head of the Food and Drug Administration, admitted that the agency’s controversial approval of the Alzheimer’s drug Aduhelm has diminished its standing with experts.
